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Abstract
Human breast milk is known to provide the most complete
nutrition to growing infants. There may be more gained
from breastfeeding than simply nutritional fulfillmentrecent research has uncovered benefits related to the development and health of infants. Breastfeeding has been shown
to stimulate immune system development by exposing the
infant to bacteria and antibodies from the mother. Breastfeeding may also benefit nursing mothers by improving insulin sensitivity and glucose tolerance as well as decreasing
postpartum weight gain. In place of breastfeeding, formulas
are able to provide an infant with necessary nutrition. Many
infant formulas have been enriched with probiotics and
prebiotics to provide formula-fed infants with similar
immune system benefits. Research on these formulas is inconclusive at this time, though hydrolyzed formulas have the
potential to prevent autoimmune diseases and food allergies. Research has found many differences between breastfed and formula-fed infants. For instance, children who had
been exclusively breastfed for more than three months
showed significantly higher cardiovascular fitness levels
than those who were formula-fed. Additionally, at 6 months
of age, breastfed infants were found to have a lower protein
intake and leaner body mass compared to formula-fed infants. The microbiome of breastfed infants also differs from
formula-fed infants, with breastfed infants having higher
concentrations of beneficial Bifidobacterium species (spp.)
and formula-fed infants hosting a wide range of potentially
pathogenic bacteria including Clostridium spp., Streptococcus spp., Staphylococcus spp. and Enterobacteriaceae family.
Pharmacists can play a vital role by providing breastfeedingrelated services to patients including education, breast
pump or infant formula selection, and counseling regarding
medication use during lactation.
Key Terms
Autoimmune; Breastfeeding; Gastrointestinal Microbiome;
Growth; Immune System; Infant; Infant Formula; Maternal
Health; Prebiotic; Probiotic
Introduction
Breastfeeding has been the primary means for feeding infants since the beginning of human existence. Yet, early man
did not realize that breast milk was not just a food source
but also a key factor in child development on the microscopic level. The advent of modern technology has allowed
scientists and researchers to look more closely at the role
breastfeeding may play in early development an~ the possible lasting effects it may produce on children as they age.
Technology has also provided parents with other options for
feeding children, as a plethora of infant formulas are marketed to meet the nutritional needs of a growing child.

Recent research suggests that differences may exist between
the development of breastfed and formula-fed infants, specifically in areas of cardiovascular health, growth, gastrointestinal flora composition and immune system function.
Studies have been conducted to examine these effects, and
this article will explore some of the facts gleaned from research. Effects on the mother and infant with regard to
weight gain, cardiovascular health, infant microbiome and
immune development and function will be discussed as well
as the role of the community pharmacist in providing
breastfeeding-related services to patients.
Health Benefits
In general, public health programs across America have
marketed that breastfeeding can benefit a child and mother
in a variety of ways, including cardiovascular fitness. Studies
suggest that the more cardiovascular exercise children complete, the less likely they are to become overweight and the
more likely they are to maintain an active lifestyle as they
grow. Labayen et al. looked at exclusive breastfeeding duration and cardiorespiratory fitness in 1,996 children and adolescents.! Cardiovascular fitness of each participant was
measured on a cycle ergometer and adjusted for country,
sex, age, pubertal status and body mass index (BMI).
Children who were exclusively breastfed for longer than
three months as infants displayed significantly higher fitness
levels than children who were formula-fed (p<0.001). With
increasing duration of breastfeeding, there was a corresponding increase in the cardiovascular fitness level.
To examine the relation of breastfeeding to maternal cardiovascular health, the HUNT-study was conducted in Norway,
the nation with the highest rate of breastfeeding in the
world.2 The study followed 21,368 women aged 20 to 85
years, focusing on their duration of lactation and cardiovascular risk factors. Worsening cardiovascular health can lead
to a greater risk of developing diseases such as type 2 diabetes. It was found that breastfeeding is most beneficial when
women are SO years of age or younger from a cardiovascular
health perspective. The HUNT-study also concluded that
breastfeeding can improve insulin sensitivity and glucose
tolerance, which is beneficial for the prevention of type 2
diabetes.
A study by McClure et al. found that the lactation method is a
predictor of future risk of developing diabetes, hypertension
and cardiovascular disease.3 This study focused on maternal
visceral adiposity in post-breastfeeding mothers. A total of
351 women aged 45 to 58 years were included. The researchers determined that maternal BMI is influenced by the
mother's choice to formula-feed or breastfeed her infant.
Mothers who breastfed consistently gained less weight and
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visceral adiposity over an eight-year period postpartum as
compared to mothers who formula-fed. "Women who had
never breastfed had 28 percent greater visceral adiposity (95
percent confidence interval (CI): 11-49, p=0.001), 4.7 percent greater waist-hip ratio (95 percent CI: 1.9-7.4, p<0.001)
and 6.49 cm greater waist circumference (95 percent CI:
3.71- 9.26, p<0.001) than mothers who breastfed all of their
children for three months or greater".3 The study adjusted
for age, parity and years since last birth as well as socioeconomic, lifestyle and family history variables. The more visceral adiposity a woman has, the higher the risk of developing diabetes, hyperlipidemia or coronary artery disease. This
information was true only for women who were not obese
during pregnancy. Women who were obese during pregnancy showed no difference in these health risks whether they
formula-fed or breastfed their infants.
Researchers have conducted numerous studies on breastfed
and formula-fed infant growth. The study by Prentice et al. is
the largest report describing human milk macronutrient contents and was the first extensive report to discover the relationship between macronutrients and infancy growth. 4 The
main factor contributing to the difference of infant growth in
breastfed versus formula-fed infants is the amount of protein
intake. Human milk was found to have lower percentage of
protein compared to formula (7.3 percent in human milk, 8.3
percent in formula milk, p<0.05). The percent of protein content was found to be positively related to BM!, which can
have an effect for years after infancy. At about 6 months of
age, breastfed infants are leaner than formula-fed infants,
most likely because of the increased caloric load in the formula compared to breast milk. The human milk contains 58.7
kcal per 100 mL compared to formula which contains 62.6
kcal per 100 mL. In summary, research indicates that breastfeeding may positively impact cardiovascular health and contribute to maintenance of a healthy weight in both infants
and mothers.

Microbiome
The gastrointestinal (GI) flora composition is important in
the digestion of complex starches along with other food
products.s Gastrointestinal bacteria are also a source of vitamins K and B12 which are both essential for functions such as
clotting and healthy nerve function. Additionally, infants
need gut bacteria to develop immune activity. The gut is first
colonized by bacteria provided by the mother through a vaginal birth, contact with skin and the mother's GI tract. A child
who is delivered vaginally, compared to cesarean delivery, is
exposed to bacteria from the mother's vagina, feces and skin.
These bacteria can be ingested through the mouth to enter
the infant's GI. After birth, the gut microbiome is further developed through the ingestion of either formula or breast
miJk.6
In breastfed infants, the microbiome is dominated by the
presence of Bifidobacteriaceae, a gram positive family of bacteria that is typically composed of anaerobes and is located in
the GI tract, among other lactic acid bacteria.6 Bifidobacteriaceae have the capability to prevent pathogenic GI infections
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and also have anticarcinogen characteristics.7 Bifidobacteriaceae are also increased in infants who were delivered
naturally at full term.6 Formula-fed infants have an entirely
different and diverse group of bacteria which dominate the
microbiome. These bacteria include Bifidobacteriaceae family as well as Bacteroides spp., Clostridum spp., Staphylococci
spp., Streptococci spp. and Enterobacteriaceae. These additional bacteria are more likely to cause pathogenic infections,
such as Clostridium difficile, than the Bifidobacteriaceae
which predominate in breastfed infants.
Additionally, human milk contains natural antimicrobial
agents which help to combat infections from GI flora.a Formula, however, does not have antimicrobial properties like
those of breast milk. Also, the infant formula of today is unable to be made sterile per current processing methods. Thus,
the microbial agents present in the formula have increased
growth potential if the formula is not stored properly.
Schwartz et al. performed a study to evaluate the microbiome of infants.7 In this study, the feces of six breastfed infants and six formula-fed infants were evaluated. Messenger
ribonucleic acid (RNA) and gut epithelial cells were extracted
from the collected feces. It was found that the formula-fed
infants had a lower overall number of bacterial genes expressed in comparison to breastfed infants. Breastfed infants
also had genes specific to promoting gut motility, such as
tachykinin receptor 1, as well as genes that are involved in
reactive oxygen species homeostasis, thus preventing
damage to the body by free radicals. However, genes that
promote mucosa! inflammation, such as vascular adhesion
protein 1 and interleukin 1 alpha, were downregulated in
breastfed infants compared to formula-fed infants.
Therefore, a higher potential GI inflammation in formula-fed
infants is expected. Additionally, the higher number of genes
expressed in breastfed infants is viewed as advantageous
because the bacteria promote a more developed and diverse
microbiome.
The current trend of using probiotics to increase gut health
has consequently led to the inclusion of probiotics in infant
formula. Several studies have been performed to evaluate the
effects of probiotics in formulas. Costeloe and colleagues performed a multicenter, randomized, controlled trial to compare the effect of Bifidobacterium (a probiotic) to placebo.9
All infants included in the study were preterm (gestational
age of 23 to 30 weeks and 6 days), with 650 infants in the
probiotic group and 660 infants in the placebo group. The
primary outcome included three main events: an episode of
necrotizing enterocolitis, sepsis or death before discharge.
Sepsis was defined as a positive blood culture of an organism
outside the realm of normal skin flora and was drawn more
than three days after birth and before 46 weeks postmenstrual age or discharge if sooner. The postmenstrual age is
defined by the gestational age plus the conceptional age
(time since birth) of the infant. None of the primary outcomes were found to be significantly different between the
probiotic and placebo groups. The following are the specific
results for the primary outcomes of the pro biotic and place-
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bo group, respectively: necrotizing enterocolitis 9 percent,
10 percent (95 percent CI of 0.68 to 1.27), sepsis 11 percent,
12 percent (CI 0.73 to 1.29), and death 8 percent, 9 percent
(CI 0.67 to 1.30). Therefore, this study found that probiotics
had no benefit in preventing necrotizing enterocolitis, sepsis or
death in preterm infants. One of the limitations of this study is
the choice of primary outcome since the prevention of serious
conditions is not the primary goal of most mothers who would
be interested in using a probiotic-enhanced formula.
lndrio and colleagues also performed a study to examine
prebiotics and probiotics in preterm newborns.lo The 49 infants studied were split into four groups, 17 infants in the
breastfed group, 10 in the prebiotic group, 10 in the probiotic group and 12 in the placebo group. The prebiotics used
were short chain galacto-oligosaccharides and long chain
fructo-oligosaccharides, which are nondigestible food products that stimulate the growth of gut bacteria. The probiotic
used was Lactobacillus reuteri, which differs from the prebiotic because it is a microorganism which replenishes the gut
flora. The primary outcome was the percentage of electrogastrography (EGG), a way to measure the electrical signals
which travel through the stomach muscles, measuring contraction and gastric emptying rate. The prebiotic, probiotic
and breastfed groups all showed statistically significant results for the primary outcome, demonstrating that feeding of
preterm infants with prebiotic or probiotic-supplemented
formulas improves gastric emptying and the maturation of
EGG activity, and does so in a way that closely mimics the
effects of breast milk.
Cekola and colleagues evaluated much more practical primary outcomes, such as mean weight gained (in grams/day).11
This study was a randomized, controlled trial which was
double-blinded and multicentered. lt included infants 14
days old (+/- three days) who were administered either a
probiotic enriched formula or a placebo formula until day
112 (+ /- three days). The probiotic Lactobacillus re uteri was
administered to 60 infants, and the placebo was administered to 62 infants. The weight of the infant was measured at
the first visit (14 days) and at the fourth visit (day 112). Secondary outcomes of head circumference and length were
also evaluated. There was no statistically significant difference in the mean weight gain between the probiotic and placebo groups (p>0.5). Mean weight gains were 29.4 g/d and
30.7 g/d for probiotic and placebo groups, respectively. Additionally, the length and head circumference were also not
statistically significant.
Another study of similar design, performed by Maldonado
and colleagues, included a three-year follow up of an earlier
study.12 The original study included infants in a probiotic
group who were administered Lactobacillus fermentum and
infants in a placebo group. The study lasted five months, and
the primary outcome was the safety and efficacy of the probiotic. Once safety and efficacy were established, a three-year
follow up was done to evaluate the primary outcome of
growth in children (including weight, length and head circumference). Secondary outcomes included incidence of inWinter 2017 Volume 8, Issue 1
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fectious and noninfectious diseases or disorders that were
related to intestinal function. For these outcomes, a portion
of the infants from the original study were evaluated (45 in
the probiotic group and 46 in the control group). The weights
of both groups were in the 75th percentile of the World
Health Organization (WHO) child growth standards. Since
neither the primary nor secondary outcomes were significant, it cannot be concluded that early administration of probiotics helps increase infant weight or decrease rate of infection. The probiotic was only administered for five months, a
short period in comparison to an infant in a practical setting
which would be breastfed for much longer, thus rendering a
weakness to the study. However, it is understandable to have
a short duration within the original study due to the primary
outcome being safety and efficacy.
Breastfed infants naturally receive more advantageous gut
flora from their mothers, helping them form a healthy gut
microbiome. Because all mothers are not able to breastfeed,
these studies have been conducted to evaluate the addition
of prebiotics and probiotics to help supplement the formulas
available. Although the evidence is contradicting at times,
and therefore cannot definitively be deemed beneficial, the
use of these supplements is safe in infants.

Autoimmune Disease Development
Thus far, the benefits of breastfeeding infants have been displayed through exploring cardiovascular health outcomes,
postpartum maternal well-being, infant growth, Gl development of the infant and prevention of life-altering infections in
infants. An infant's gut microbiota contributes to immune
system development and may impact the development of
autoimmune diseases. 13 Breast milk contains regulatory
cytokine transforming growth factor-b (TGF-b ), secretory
immunoglobulin A (IgA) antibodies and the innate immune
receptor soluble CD14, all of which help to build an infant's
immune defenses.1 4 However, it is unclear if these bioactive
factors alone are enough to combat the development of autoimmune diseases. Formula-fed infants and breastfed infants
develop different gut microbiomes. The combination of an
infant's environmentally decided microbiome with the
infant's genetic predisposition to develop certain diseases
influences the development of type 1 diabetes mellitus
(TlDM), rheumatoid arthritis (RA) and atopic eczema/
dermatitis syndrome (AEDS).
Type 1 Diabetes Mellitus (TlDM)
Type 1 diabetes mellitus develops when pancreatic islet f3cells do not produce enough insulin due to autoimmune destruction.ts While biological factors, such as the presence of
the human leukocyte antigen (HLA) complex gene, do contribute to risk of TlDM, environmental factors such as infant
nutrition are also instrumental in determining if the disease
will develop. Breastfed infants have a decreased gut permeability to enterovirus infections in comparison to formula-fed
infants. Since enterovirus infections can trigger the development of fl-cell autoimmunity, breastfeeding may help prevent
TlDM. To investigate the relationship between infantile feeding patterns and the development of TlDM in infants with
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the HLA gene, Lund-Blix et al. took blood samples and surveyed 726 children carrying the HLA gene at ages 3, 6, 9 and
12 months and then annually. Survey questionnaires gathered data about the types of milk consumed, vitamin supplements administered and whether solid food had been introduced to the infant. Statistical analysis of this data revealed
that the duration of breastfeeding did not significantly differ
between those who developed TlDM and those who did not
(p=0.44). However, further investigation did reveal that
"breastfeeding for 12 months or longer predicted a lower
risk of progressing [from islet autoimmunity] to TlDM" with
a hazard ratio of 0.35 (95 percent CI [0.13-0.94]).15 Similarly,
Rabiei investigated the duration of exclusive breastfeeding in
100 Iranian children diagnosed with TlDM and 200 nondiabetic Iranian children. 16 Children who were breastfed for
fewer than four months were found to have higher instances
of TlDM (p<0.008). Although Rabiei did not control for genetic contributions to the development of disease, these results suggest that exclusive breastfeeding for at least four
months may have a preventive effect on the development of
TlDM.
Furthermore, a case-control, retrospective study performed
in the Czech Republic by Malcova et al. obtained questionnaires from 868 parents of children with TlDM and 1,466
parents of children who had not been diagnosed with
TlDM.17 Survey questions gathered information about infant
feeding patterns including duration of breastfeeding, timing
of introduction to formula and supplementation with vitamin
D. Statistical analysis displayed a correlation between a lack
of breastfeeding and a risk of developing TlDM (OR=l.93).
Moreover, extending breastfeeding to 12 months or longer
appeared to have a negative correlation with the development of TlDM (OR=0.42). A similar case-control study was
performed in Brazil by Alves et al., but the control subjects
were the siblings of children diagnosed with T1DM. 1B Overall,
123 children with TlDM, along with their respective siblings,
were assessed based on rates and duration of breastfeeding
as an infant. Although children with TlDM and their nondiabetic siblings had similar rates of breastfeeding, children
who developed the disease were breastfed for shorter durations (3.3 versus 4.6 months, p<0.001).
This possible connection between breastfeeding and the development of TlDM has caught the attention of a global audience. Due to this widespread interest, the Trial to Reduce
Insulin-Dependent Diabetes Mellitus in the Genetically at
Risk (TRIGR) study was initiated in 77 centers across 15
countries.19 The TRIGR project is a randomized, doubleblind, controlled intervention trial designed to explore the
question of whether weaning to an extensively hydrolyzed
formula in infancy will decrease the risk of TlDM in later
childhood. Researchers recruited 5,606 newborns with family members affected by TlDM and 2,159 carrying the HLA
genotype for this study. The TRIGR study will not be completed until 2017, but it seeks to provide uniform data regarding the benefits and consequences of supplementing
infants at a higher genetic risk with hydrolyzed formula to
prevent TlDM.
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Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a chronic, inflammatory, autoimmune disease that causes pain and deformity of the joints.
For postpartum women with RA, breastfeeding for at least 13
months has been associated with decreasing signs and symptoms of the disease. 20 In addition, recent studies have explored the positive protective benefits of breastfeeding for
the infant who may genetically be at risk of developing RA
secondary to the mother's diagnosis. Parents of 688 of the
1,386 children involved with Diabetes Autoimmunity Study
in the Young (DAISY) consented to have the child's blood
tested for rheumatoid factor (RF) to evaluate the risk of RA
development.21 Children who were HLA genotype negative
(not genetically at risk for TlDM) but RF positive were less
likely to have been breastfed for longer than three months
(OR=0.18). This statistic suggests that breastfeeding could
have a protective effect against the development of RA. However, none of the children in this study developed RA, nor
were they physically examined.

In contrast, Simard et al. retrospectively examined how long
adults with RA were breastfed as infants.22 This study was a
subgroup analysis of women with confirmed RA who had
taken part in the Nurses' Health Study (NHS) and the Nurses'
Health Study II (NHSII). While breastfeeding for longer than
nine months seemed to be protective against RF-negative RA
in the NHS cohort (RR=0.6), no other breastfeeding duration
appeared to be significantly associated with RF-negative or
RF-positive RA. Furthermore, having been breastfed was not
associated with RA in either cohort, resulting in a combined
RR of 1.0. These results suggest that infants who lack a genetic risk for RA may experience protective benefits of breastfeeding.
Ultimately, research findings discussing the benefits of
breastfeeding and their effect on RA are inconsistent. This
may be due to multiple confounding factors, such as tobacco
smoke exposure, birth weight, maternal diet or simply an
inability to accurately recall breastfeeding lengths.20 Moreover, RA may not develop until much later in life which makes
correlating the effects of breastfeeding as an infant with the
prevention of this disease a difficult task.
Atopic Eczema/Dermatitis Syndrome (AEDS)
When discussing the role of breastfeeding in the prevention
or development of atopic disease, literature findings have
been inconsistent. However, AEDS is often associated with an
increased occurrence of food hypersensitivities. Hypothetically, the levels of IgA and IgE within breast milk mediate the
development of AEDS as well as several food allergies.23
Thus, AEDS development can be controlled through infantile
feeding habits and there is a possibility that allergy development could be prevented. Schoetzau et al. randomly assigned
1,172 study subjects into one of four cohorts to investigate
the relationship between style of feeding and the development of AEDS. The cohorts included the following: exclusively breastfed, cow's milk formula-fed, partially bottle-fed and
exclusively bottle-fed. At 1 year of age, the infants who were
exclusively breastfed were 47 percent less likely to develop
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AEDS than the cow's milk formula group (p=0.015).
Likewise, Chiu et al. evaluated 186 children for four years to
examine the correlation between breastfeeding and the development of atopic diseases.24WhiJe Chiu et al. found that
breastfeeding for greater than six months was correlated
with a lower occurrence of AEDS (p=0.015), partial breastfeeding for less than six months was associated with an increased risk of eczema at 1 year of age (p=0.046) and 2 years
of age (p=0.006).
A limitation of these two studies by Schoetzau et al. and Chiu
et al. is that they only investigated the effect of breastfeeding
on AEDS development in the first one to two years of
life. However, Bergmann et al. performed a cohort study including 1,314 infants who were followed from birth to 7
years of age.zs This study discovered that the prevalence of
AEDS increased with each year of life (OR=l.05) and with
each year of breastfeeding (OR=l.03). Unlike Schoetzau et al.
and Chiu et al., Bergmann et al. focused on parental history
and its relationship to the development of AEDS in high risk
infants (OR=2.06). Similarly to Bergmann et al., Ito and Fujiwara studied 38,757 infants from birth to age 42 months
using questionnaires which surveyed pattern and duration of
infant feeding and the development of AEDS.26 Results from
these questionnaires indicated a significant correlation between longer exclusive breastfeeding and the development of
AEDS (p < 0.001). This further supports the findings of Bergmann et al., suggesting that a prolonged period of breastfeeding increases an infant's risk of developing AEDS. Schoetzau
et al. and Chiu et al.'s findings contradict Bergmann et al. and
Ito et al.'s findings in that, with longer duration of breastfeeding in infancy, the risk of developing AEDS is increased with
increased age. Further confounding this debate, JeldingDannemand et al. evaluated 335 children with asthmatic
mothers for risk factors of AEDS (increased IgE levels and
skin pricks) and correlated these factors with the duration of
breastfeeding.27 Results from this study found no significant
association between exclusive breastfeeding and the development of eczema in the genetically at-risk children within
the first six years of life.

Ultimately, the correlation between AEDS and breastfeeding
is highly controversial with several confounding factors such
as parental smoking, genetic risk, timing of introduction of
solid foods and having domestic pets in the household. From
these conflicting results, it is difficult to make an absolute
conclusion regarding the effects of breastfeeding on the development of AEDS. With inconclusive information regarding
breastfeeding's direct impact on the development of AEDS,
several researchers moved to evaluate the effectiveness of
probiotics in reducing the occurrences of AEDS. Dotterud et
al. enrolled 415 pregnant women in a randomized, doubleblind trial in which the participants consumed either probiotic-infused milk or a placebo from 36 weeks of gestation
until three months postpartum.20 The probiotics included in
the supplemented milk were Lactobacillus rhamnosus GG,
Lactobacillus acidophilus La-5 and Bifidobacterium animalis.
The children of these women were evaluated at age 2 years
for the presence of AEDS. Dotterud et al. ultimately found a
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correlation between probiotic use in the mothers and a decreased incidence of AEDS (p=0.013). Supplementing the
mother with probiotics thus supplemented her breast milk
and her nursing child.
Similarly, Viljanen et al. divided 230 infants into three differing feeding groups and evaluated their genetic predisposition
for developing AEDS. 29 Group 1 consumed Lactobacillus
rhamnosus within their formula while group 2 was supplemented with Lactobacillus rhamnosus, Bifidobacterium
breve and Propionibacterium freudenreichii. Group 3 received placebo supplementation. Genetic predisposition was
assessed through skin prick results and lgE levels. Infants
were only included in the study if these findings indicated a
risk for AEDS. Infants with elevated levels of IgE who were in
group 1 displayed a decreased occurrence of AEDS symptoms in comparison to infants in the placebo group
(p=0.036). This statistical significance suggests that supplementing infants who are at risk for AEDS with Lactobacillus
rhamnosus may reduce outbreaks of skin irritation.
Similarly, Kukkonen et al. studied 1,223 pregnant women
who either received a prebiotic and probiotic treatment or a
placebo for two to four weeks prior to birth.13 Following
birth, infants received the same combination treatment or
placebo for six months. At a two year follow-up evaluation,
infants with mothers who had received the treatment had a
reduced incidence of AEDS (p=0.025). The combination of
these consistent results further reinforces the suggestion
that altering the gut microbiota of infants at high-risk for
developing AEDS by adding probiotics to the infants' diets
can prevent the development of this disease.
Role of the Pharmacist
Community pharmacists are easily accessible to the public
and are, therefore, in a unique position to provide education
and services related to breastfeeding.3o Providing patients
with facts that have been discovered through scientific research will help patients make fully informed decisions about
whether to breastfeed. However, studies show that while
pharmacists are willing to educate patients about breastfeeding, pharmacists lack education on the subject themselves. It
has been suggested that including breastfeeding in pharmacy
school curriculums and providing information about breastfeeding to practicing pharmacists through continuing education can reduce this information gap.
Perhaps most pertinent to the pharmacist is the ability to
counsel patients on medication use during lactation.31 It is
important to note that U.S. Food and Drug Administration
(FDA) pregnancy risk categories assigned to medications are
not applicable to breastfeeding. It is always best to avoid
medications or alternative medicines during lactation; however, if a medication is needed for the mother, the risks to the
infant are minimal as the amount of drug in the breast milk is
generally less than 10 percent of the maternal dose. For this
reason most drugs are considered safe for use during breastfeeding, but each case should be evaluated for safety based
on characteristics of the drug, infant age and weight, and
whether the infant was premature or a low birth weight.
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When choosing a medication for a nursing patient to treat a
common ailment such as a cold or pain, drugs with short
half-lives or high protein binding are preferred. It should be
noted that the age and weight of the infant can play a role in
possible harm from a drug. Older and heavier infants will be
able to metabolize a drug excreted in breast milk with reduced risk of side effects or harm. Use of local topical agents,
such as eye drops, should be encouraged whenever possible.
Medications that should not be used while breastfeeding include antineoplastic agents, ergotamine, methotrexate and
radiopharmaceuticals.
Trained pharmacists can also help parents select an appropriate formula or breastfeeding pump.3 2 There are many options for infant formula available, and, with the proper
knowledge, a pharmacist is a great resource to assist parents
in choosing a formula. Pharmacists can also help mothers
choose an appropriate breast pump to meet their individual
needs and can provide instructions for using the pump. Under the Affordable Care Act, most private health insurance
plans are required to pay for breast pumps under the umbrella of women's preventive health services, although this
may not apply to grandfathered plans. Breast pumps may
also be covered under some state Medicaid programs which
will vary from state to state. Pharmacists may direct patients
to contact their Medicaid provider to determine if breast
pumps are covered by their state Medicaid program. If a patient is unable to get a breast pump through Medicaid, a
pharmacist may suggest that the patient seek assistance
through the Special Supplemental Nutrition Program for
Women, Infants and Children (WIC).
Conclusion
Research has shown several differences between the health
and development of breastfed infants compared to
formula-fed infants. One difference is the composition of gut
microbiota-breastfed infants have higher concentrations of
beneficial bacteria, including Bifidobacterium spp., while
formula-fed infants have more potentially pathogenic bacteria including Clostridium spp., Staphylococcus spp. and
Enterobacteriaceae. Breastfeeding may have a positive impact on the development of a child's immune system while
formula feeding has been linked to increased incidence of
allergies. However, hydrolyzed formulas and formulas fortified with prebiotics may have protective effects against food
allergies. Additionally, breastfeeding has been shown to actively stimulate an infant's immune system and can enhance
the child's response to vaccinations. Breastfeeding has also
been shown to benefit the health of the nursing mother as
well as the infant. Breastfeeding has been linked to higher
fitness levels in infants as well as increased insulin
sensitivity and reduced postpartum weight gain in mothers.
Pharmacists can assist in educating patients about breastfeeding and preparing patients to make a fully informed
choice about whether to breastfeed. Pharmacists are also
able to help parents select an appropriate infant formula or
breast pump as well as counsel patients on the safety of medication use during lactation.
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